Subscribe: pubmed: Eur J Hem[jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rmp-ilgffswpASPNHcEa4stRoF-4Pw81Cv5l8E75TL
Preview: pubmed: Eur J Hem[jour]

pubmed: Eur J Hem[jour]



NCBI: db=pubmed; Term="European Journal of Haematology"[jour]



 



Von Willebrand disease - The "Dos "and "Don'ts" in Surgery.

Von Willebrand disease - The "Dos "and "Don'ts" in Surgery.

Eur J Haematol. 2016 Sep 13;

Authors: Miesbach W, Berntorp E

Abstract
Von Willebrand disease (VWD) is the most common genetic bleeding disorder. VWD is caused by a deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and binds and stabilises coagulation factor VIII (FVIII) in the blood. Prophylaxis of surgical bleeding in patients with VWD requires consideration of the individual situation, including the type of procedure and the bleeding rate, before decisions about treatment type, dose, duration and adjunctive therapy with antifibrinolytics or antithrombotic prophylaxis can be made. Although desmopressin (DDAVP)-stimulated release of endogenous VWD is an effective treatment strategy in many patients, plasma concentrates containing VWF are the preferred option for most patients undergoing surgical procedures. Recommendations for the management of surgery in patients with VWD are summarised, including the severity of VWD and the type of the surgical procedure. This article is protected by copyright. All rights reserved.

PMID: 27622750 [PubMed - as supplied by publisher]




Brazilian guidelines on HSCT in acute myeloid leukemia.

Brazilian guidelines on HSCT in acute myeloid leukemia.

Eur J Haematol. 2016 Sep 13;

Authors: Silla L, Dulley F, Saboya R, Kerbauy F, de Moraes Arantes A, Pezzi A, Gross LG, Paton E, Hamerschlak N

Abstract
INTRODUCTION/ OBJECTIVES: Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults. In Brazil the mortality from myeloid leukemias was 1.74/100.000 men and 1.37/100.000 women. Our aim is to review and update guidelines of the Brazilian Society of Bone Marrow Transplantation on indications of hematopoietic stem cell transplantation (HSCT) for the treatment AML CONCLUSIONS: 1) Allo-HSCT is recommended for high-risk AML (IA); 2) Allo-HSCT is recommended for AML of intermediate risk (IA); 3) Allo-HSCT is recommended for AML relapsed / refractory (C4); 4) Auto-HSCT is recommended for AML after 1 consolidation (C4); 5) Auto-HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); 6) Auto-HSCT is accepted for AML M3 in second molecular complete remission (2B); 7) Peripheral Blood instead of Bone Marrow HSC for advanced disease (2A); 8) Recommended conditioning protocols: Bu-Cy / Bu-Mel, Bu-Flu, TBI-Cy. In umbilical cord HSCT consider ATG based protocols (2A); 9) Allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 years with good performance status and absence of significant comorbidities (C4). This article is protected by copyright. All rights reserved.

PMID: 27621140 [PubMed - as supplied by publisher]